ML-9 - C15H17ClN2O2S • HCl - Bertin Bioreagent

Confirm delete?

ML-9

Zoom

Cat No: 10010236

Biochemicals - Kinase Inhibitors

ML-9 was originally identified as a selective Ca2+-calmodulin-dependent myosin light chain kinase inhibitor. Concentrations from 10-100 µM are effective at inhibiting vascular smooth muscle tension and reducing intracellular Ca2+ concentrations.{15194...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

1-[(5-chloro-1-naphthalenyl)sulfonyl]hexahydro-1H-1,4-diazepine, monohydrochloride

Correlated keywords:

PKB Akt inhibitors inhibits inhibition serine/threonine kinase PKA P90S6 MAP kinases cancers anti-cancers insulin glucose transports calcium channels calmodulin intracellular smooth muscles asthma

Product Overview:
ML-9 was originally identified as a selective Ca2+-calmodulin-dependent myosin light chain kinase inhibitor. Concentrations from 10-100 µM are effective at inhibiting vascular smooth muscle tension and reducing intracellular Ca2+ concentrations.{15194} ML-9 also inhibits PKB/Akt activity with an IC50 range of 10-50 µM in rat primary adipocytes. This results in a specific inhibition of insulin-stimulated glucose transport and GLUT4/IGF II receptor translocation to the plasma membrane yet does not interfere with the antilipolytic effect of insulin.{15239} Additionally, ML-9 inhibits other serine/threonine kinases including PKA (IC50 = ~20 µM), p90 S6 (IC50 = ~50 µM), and MAP kinase (IC50 = ~35 µM).{15239}

Size	10 mg
Shipping	dry ice
CAS Number	105637-50-1
Molecular Formula	C₁₅H₁₇ClN₂O₂S • HCl
SMILES	ClC1=CC=CC2=C1C=CC=C2S(=O)(N3CCCN([H])CC3)=O.Cl
Molecular Weight	361,3
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2930.90
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.